Investigating cardiac amyloidosis in Tunisian patients with heart failure
Prevalence of Cardiac Amyloidosis in Heart Failure Patients With Preserved Left Ventricular Ejection Fraction in Tunisia
University Tunis El Manar · NCT06201832
This study looks at how common cardiac amyloidosis is in older Tunisian patients with heart failure to see if certain signs can help doctors spot it earlier.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 87 (estimated) |
| Ages | 60 Years to 90 Years |
| Sex | All |
| Sponsor | University Tunis El Manar (other) |
| Locations | 1 site (La Marsa, Tunis) |
| Trial ID | NCT06201832 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on assessing the prevalence of cardiac amyloidosis (CA) in Tunisian patients diagnosed with heart failure with preserved ejection fraction (HFpEF). The study aims to identify clinical and echocardiographic criteria that could help predict the presence of CA, which is often underdiagnosed despite its significant impact on patient outcomes. By analyzing data from patients with specific heart conditions, the researchers hope to improve early diagnosis and treatment strategies for CA. The study highlights the importance of recognizing CA as a common cause of HFpEF in the elderly population.
Who should consider this trial
Good fit: Ideal candidates for this study are Tunisian patients aged 60 and older who have been diagnosed with HFpEF and exhibit specific echocardiographic findings.
Not a fit: Patients under 60 years of age or those with acute coronary syndrome or congenital heart disease will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier diagnosis and improved management of cardiac amyloidosis in patients with heart failure.
How similar studies have performed: Other studies have indicated that early diagnosis of cardiac amyloidosis can significantly improve patient outcomes, suggesting that this approach may yield beneficial results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * HFpEF during the previous year * IVS thickness of 12mm or greater Exclusion Criteria: * age under 60 years * Acute coronary syndrome complicated by HFpEF * Congenital heart disease
Where this trial is running
La Marsa, Tunis
- Security Hospital Forces — La Marsa, Tunis, Tunisia (RECRUITING)
Study contacts
- Principal investigator: Lilia Zakhama, Prof — University of Tunis El Manar, Faculty of Medicine of Tunis, Tunisia
- Study coordinator: Lilia Zakhama, Prof
- Email: lilia.zakhama@fmt.utm.tn
- Phone: 98345427
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Cardiac Amyloidosis, Heart Failure With Preserved Ejection Fraction, Echocardiography, CMR, Bone Scintigraphy, Prevalence, Diagnosis